Abstract
Idarucizumab, a humanized monoclonal antibody fragment, for reversal of Dabigatran therapy for atrial fibrillation
Highlights
The prevalence of atrial fibrillation (AF) increases with age, and the elderly are the fastest growing subset of the population
Antithrombotic therapy reduces the risk of stroke in patients with AF, and Warfarin has been shown to have a relative risk reduction of approximately 60% compared with control and to be significantly more effective than Aspirin [16,17]
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) was a large, multicenter, randomized trial designed to compare two fixed doses of Dabigatran (110 mg and 150 mg), each administered in a blinded manner, with open-label use of Warfarin in AF patients who were at increased risk for stroke [19]
Summary
The prevalence of atrial fibrillation (AF) increases with age, and the elderly are the fastest growing subset of the population. The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) was a large, multicenter, randomized trial designed to compare two fixed doses of Dabigatran (110 mg and 150 mg), each administered in a blinded manner, with open-label use of Warfarin in AF patients who were at increased risk for stroke [19]. The primary net clinical benefit outcome was the composite of stroke, systemic embolism, pulmonary embolism, myocardial infarction, death, or major hemorrhage.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call